SymbolSNGX
NameSOLIGENIX, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address29 EMMONS DRIVE,SUITE B-10, PRINCETON, New Jersey, 08540, United States
Telephone+1 609 538-8200
Fax
Email
Websitehttps://www.soligenix.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0000812796
Description

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Additional info from NASDAQ:
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

2026-06-25 16:28

New Form SCHEDULE 13G - SOLIGENIX, INC. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0002103370-26-000002 <b>Size:</b> 44 KB

Read more
2026-06-18 02:14

SNGX attributes changed: Attr: Fin_status N -> D;

Read more
2026-06-18 02:14

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Read more
2026-06-18 02:03

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Read more
2026-06-08 11:32

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Read more
2026-05-28 21:21

(99% Neutral) SOLIGENIX, INC. (SNGX) Announces Business Combination

Read more
2026-05-28 18:20

New Form 424B5 - SOLIGENIX, INC. <b>Filed:</b> 2026-05-28 <b>AccNo:</b> 0001104659-26-067644 <b>Size:</b> 23 KB

Read more
2026-05-26 11:32

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Read more
2026-05-08 17:17

New Form 424B3 - SOLIGENIX, INC. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001104659-26-057944 <b>Size:</b> 920 KB

Read more
2026-05-08 17:14

New Form 424B3 - SOLIGENIX, INC. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001104659-26-057936 <b>Size:</b> 919 KB

Read more